Skip to content
Investing

BrainChip Holdings: An Investor Profile of the Neuromorphic Edge AI Chip Designer

BrainChip Holdings licenses brain-inspired AI chip designs and sells its own AKD1500 chips and boards. Its products, latest cash figures, share count, risks and the milestones ahead.

BrainChip's release image for its AKD1500 Raspberry Pi 5 developer kit
Photo: BrainChip Holdings

BrainChip Holdings designs AI processors modelled loosely on how the brain handles signals, aimed at small, battery-powered devices rather than data centres. After years of slow sales it is shipping its own chips and boards in volume for the first time, but revenue is still small and its cash covers about a year of spending.

What BrainChip does

BrainChip is registered in Australia, with its office in Sydney, and issues its product news from Laguna Hills in California. Its shares trade on the ASX as BRN, over the counter in the US as BRCHF and as BCHPY American depositary receipts. It reports in US dollars and publishes quarterly cash-flow reports. Sean Hehir is chief executive.

Its core technology is Akida, a fully digital, event-based processor. Rather than crunching all incoming sensor data, it analyses only the essential inputs, which BrainChip says cuts power use. It targets devices that must run AI locally, such as wearables, industrial sensors, drones, radar and space systems. Its own neural network models, called TENNs, build on state-space models designed for streaming data.

BrainChip makes money in three ways:

  • IP licences and royalties: chipmakers license Akida or the new Sequora design and build it into their own chips. Sequora, released for licensing in October 2026, adds generative AI and on-device language models, with compute that BrainChip puts at up to 3 billion parameters and beyond.
  • Chips: the AKD1500 co-processor, now offered in a PCIe version and, since October, an SPI version that connects to the microcontrollers already inside many devices.
  • Boards and kits: M.2 and PCIe cards, a Raspberry Pi 5 kit and the AkidaTag reference platform. The AKD1500 SPI chip is sold through BrainChip's online shop and the distributor DigiKey.

BrainChip Holdings: share price, chart and news

BrainChip's release image for its AKD1500 PCIe evaluation card.
BrainChip's release image for its AKD1500 PCIe evaluation card. Photo: BrainChip Holdings

Key numbers

MeasureLatest figure
Cash, 30 Sept 2026US$16.4m
Cash, 30 June 2026US$20.3m
Net operating cash outflow, Sept quarterUS$4.3m
Customer receipts, Sept quarterUS$0.27m
Customer receipts, nine monthsUS$1.09m
Net operating cash outflow, nine monthsUS$15.6m
Funding availableAbout 3.95 quarters, per the company
Shares on issueAbout 2.28bn, per ASX data

ASX data this week showed the shares trading at about A$0.10 to A$0.11, at the bottom of a 52-week range of A$0.10 to A$0.205. At A$0.105 that gives a market value of about A$240m.

Customers and licensees

Who is using BrainChip's technology

  • Parsons: the US defence contractor has received its full initial order of 10,000 AKD1500 chips and is building M.2 boards with four, eight or twelve chips
  • Onsor Technologies: a 2,000-chip order for Nexa EEG glasses that detect epileptic seizures, awaiting approval from Oman's Ministry of Health
  • Neuromorphyx: 1,200 chips for its BrainBoard1500, plus chips to build boards that BrainChip sells
  • EdgeAI (Korea): licensed Akida 2 in March 2026, plans a December tape-out and samples in early 2027 for smart meters
  • Frontgrade Gaisler: licensed Akida in December 2024 for a space chip, the GR801, with production expected in 2027

BrainChip also lists partnerships with automated optical inspection company Orama.AOI and an Akida bundle for IBM's Spectrum Symphony workload software. Most of these are evaluations or small orders rather than large recurring contracts.

The shift to selling its own silicon has happened quickly. BrainChip received its first 2,000 AKD1500 chips in June 2026, began filling orders in July, released its M.2 board the same month and took delivery of about 20,000 more chips in September. It added two sales executives during the quarter. Because plug-in boards let engineers test Akida in standard computers, the company sees easier evaluation as one of the main levers for turning interest into orders.

The main risks

Funding and dilution. BrainChip has spent much more than it has received for years. With about US$16.4m and quarterly operating outflows of more than US$4m, the company's own estimate is just under four quarters of funding, so new money is likely to be needed unless receipts grow. The company says it reviews funding options regularly. Its previous funding agreement with LDA Capital has ended, after LDA sold its last collateral shares in August.

Slow adoption. In a September letter to shareholders, the board acknowledged that the edge AI market had taken longer to mature than first expected. Royalties only start when licensees reach production, which the company says could potentially begin in late 2027.

Execution and supply. Its AKD2500 chip and two licensee chips are due to tape out around December. First AKD2500 samples are expected early in the third quarter of 2027, subject to foundry capacity, which the company says has been tight throughout 2026.

Governance. Two former directors are leading an activist campaign seeking a shareholder meeting and changes to the board, which the board has rejected in open letters. The ASX also found that BrainChip should have released its September letter to the market at the time; the company says it has updated its procedures.

Competition. BrainChip competes with far larger chip companies for a place in device makers' designs. It cites a Spherical Insight ranking that puts it third in neuromorphic AI behind Intel and IBM, which it says have no production-grade neuromorphic chips.

What to watch next

TimingEvent
End of November 2026Remaining AKD1500 chips from the production run
December 2026AKD2500 tape-out and EdgeAI wafer tape-out
Coming monthsFrontgrade Gaisler GR801 tape-out; Parsons board availability
Late January 2027December quarter Appendix 4C, with cash and receipts
Q1 2027EdgeAI engineering samples
Early Q3 2027First AKD2500 engineering samples
Late 2027Possible start of royalty revenue

Investors will also watch whether the activist group gathers enough support to force a shareholder meeting, and whether Sequora wins its first licence.

Sources

Related stories

Markets

BrainChip Holdings Ends the September Quarter With US$16.4m as Chip Shipments Grow

BrainChip Holdings ended September with US$16.4m in cash, about four quarters of runway, after receiving 20,000 AKD1500 chips. Two licensees aim to tape out chips by year end.

Investing

Talga Group: An Investor Profile of the Swedish Graphite Anode Developer

Talga Group mines no graphite yet, but it sells small volumes of anode from a Swedish demonstration plant. Its assets, customers, cash, share count, risks and the dates that matter…

Investing

Athabasca Oil Profile: What Cenovus Is Buying Ahead of the 27 November Vote

Athabasca Oil's thermal projects, Duvernay stake, third-quarter numbers and balance sheet, plus the election deadline and the risks for shareholders before the vote on the C$12…

Investing

Sigma Lithium: An Investor Profile of the Brazilian Producer After Its Stop-Start Year

Sigma Lithium mines and processes lithium in Minas Gerais, Brazil. Its operation, latest numbers, debt and new bond, expansion plans, the legal and liquidity risks, and the dates…

Investing

Aya Gold & Silver Corrects Q3 Cash Costs to $14.28 an Ounce After Silver Double Count

Aya Gold & Silver refiled its Q3 MD&A after silver in transit was deducted twice. Zgounder ounces sold rise to 1,392,478 and cash costs fall to $14.28 from $15.51. Revenue and…

Investing

FDA Rejects Summit's Lung Cancer Drug Ivonescimab Over Phase 3 Survival Miss

The FDA has rejected Summit Therapeutics' lung cancer drug ivonescimab, saying slower tumour growth in the phase 3 HARMONi trial was not enough without a clear gain in survival.

Investing

Red Cat Withdraws Its $150m to $180m 2026 Revenue Target After $11.8m Third Quarter

Red Cat Holdings has withdrawn its $150m to $180m revenue target for 2026 after third-quarter sales of $11.8m, blaming slower defence funding. Its quarterly net loss more than…

Investing

Berkshire Reveals $689m Bending Spoons Stake, Doubles Lennar and Trims Bank of America Again

Berkshire Hathaway's third-quarter 13F shows a new Bending Spoons stake worth $689m, a doubled Lennar holding and 27.5 million more Bank of America shares sold, while Apple stayed…